Status:
COMPLETED
A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Treatment of patients with cancer types known to express the HER-2 and/or CEA tumor antigens.
Detailed Description
The optional followup period for this study is 1 year after the last vaccination.
Eligibility Criteria
Inclusion
- Patients must have completed surgical treatment for his/her primary disease at least 1 month prior to enrollment
- Patient must not be pregnant 3 days prior to enrollment
Exclusion
- Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent
- Patient has had their spleen removed or has a history of autoimmune disorders
- Patient is a regular user of any illicit drugs or has used within the past year of drug or alcohol abuse
- Patient is pregnant or breastfeeding or is expecting to conceive anytime following the study
- Patient is known to be Human Immunodeficiency Virus (HIV)-seropositive
- Patient has a known history of Hepatitis B or C
- Patient has received a vaccine for any disease or condition within one month of enrollment
- Patient has a primary central nervous system tumor.
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00647114
Start Date
August 1 2007
End Date
April 1 2009
Last Update
March 13 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.